免疫检查点抑制剂相关心血管不良反应流行病学、发病机制及诊断与治疗进展
Progress on Epidemiology,Pathogenesis,Diagnosis and Treatment of Immune Checkpoint Inhibitors-Related Cardiovascular Adverse Events
于坚 1王江涛 2刘新亚 3史敬 1李妍 1吴莉 4张源明3
作者信息
- 1. 830000 新疆维吾尔自治区乌鲁木齐市,新疆医科大学附属肿瘤医院肿瘤心脏病科;830000 新疆维吾尔自治区乌鲁木齐市,新疆医科大学
- 2. 830000 新疆维吾尔自治区乌鲁木齐市,新疆军区总医院心胸外科
- 3. 830000 新疆维吾尔自治区乌鲁木齐市,新疆医科大学
- 4. 830000 新疆维吾尔自治区乌鲁木齐市,新疆医科大学附属肿瘤医院肿瘤心脏病科
- 折叠
摘要
免疫检查点抑制剂(ICIs)作为临床治疗肿瘤的一线药物,其治疗过程中会引发一系列免疫相关不良反应(irAEs),涉及多器官、多系统,其中最严重的是ICIs相关心血管不良反应,主要包括心肌炎、心包炎、动脉粥样硬化性心血管疾病、心律失常、血管炎、静脉血栓栓塞等.ICIs相关心血管不良反应发生率虽低,但死亡率较高,已严重影响肿瘤患者的生存质量及远期预后,因此早期识别和及时干预至关重要.本文主要综述了ICIs相关心血管不良反应的流行病学、发病机制、诊断与治疗,以期为临床工作提供参考.
Abstract
Immune checkpoint inhibitors(ICIs),as a first-line drug for clinical treatment of tumors,can cause a series of immune-related adverse events(irAEs)during the treatment,involving multiple organs and systems.The most serious of them are ICIs-related cardiovascular adverse events,including myocarditis,pericarditis,atherosclerotic cardiovascular disease,arrhythmia,vasculitis,and venous thromboembolism.Although the incidence of ICIs-related cardiovascular adverse events is low,the mortality rate is high,which has seriously affected the quality of life and long-term prognosis of cancer patients.Therefore,early identification and timely intervention are very important.This article mainly reviews the epidemiology,pathogenesis,diagnosis and treatment of ICIs-related cardiovascular adverse events,in order to provide reference for clinical work.
关键词
抗肿瘤药,免疫/免疫检查点抑制剂/心血管不良反应/综述Key words
Antineoplastic agents,immunological/Immune checkpoint inhibitors/Cardiovascular adverse events/Review引用本文复制引用
出版年
2025
国家科技期刊平台
NSTL
维普
万方数据